This study investigated the severity of hirsutism and its correlation with serum total testosterone (tT) levels in 87 patients with polycystic ovary syndrome (PCOS) and 85 healthy control subjects from the south-eastern region of Turkey. A wide range of variability exists in both hirsutism and modified Ferriman—Gallwey (mFG) scores. Similar mFG scores and serum tT levels were found compared with previous studies of general populations, but lower scores than those previously reported from Turkey. The incidence of hirsutism was lower in hyperandrogenic PCOS patients compared with non-hyperandrogenic PCOS patients. There was no correlation between serum tT levels and the rate of hirsutism in patients with PCOS. Heritability, testosterone receptor sensitivity, 5α reductase activity or environmental/socioeconomic factors may play a role in the development of clinical hirsutism. Larger scale studies are needed to clarify which other factors may be responsible and to confirm these results.
AzzizRWoodsKSReynaR: The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab2004; 89: 2745–2749.
2.
Diamanti-KandarakisEKouliCRBergieleAT: A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab1999; 84: 4006–4011.
3.
Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod2004; 19: 41–47.
4.
FerrimanDGallweyJ: Clinical assessment of body hair growth in women. Clin Endocrinol1961; 21: 1440–1447.
5.
LorenzoEM: Familial study of hirsutism. J Clin Endocrinol1970; 31: 556–564.
6.
HatchRRosenfieldRLKimMH: Hirsutism: implications, etiology, and management. Am J Obstet Gynecol1981; 140: 815–830.
7.
MichelmoreKFBalenAHDungerDB: Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf)1999; 51: 779–786.
8.
ConwayGSHonourJWJacobsHS: Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxf)1989; 30: 459–470.
9.
LegroRSMyersERBarnhartHX: The pregnancy in polycystic ovary syndrome (PPCOS) study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril2006; 86: 914–933.
10.
HahnSTanSElsenbruchS: Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia. Horm Metab Res2005; 37: 438–444.
11.
ChangWYKnochenhauerESBartolucciAA: Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril2005; 83: 1717–1723.
CoskunAErcanOArikanDC: Modified Ferriman—Gallwey hirsutism score and androgen levels in Turkish women. Eur J Obstet Gynecol2010; 154: 167–171.
14.
ClassRHKaseNG: Anovulation and polycystic ovary syndrome. In: Clinical Gynecologic Endocrinology and Infertility, 7th edn (SperoffLFritzMA, eds). Philadelphia: Lippincott, Williams & Wilkins, 2004: pp 465–469.
15.
AzzizRCarminaEDewaillyD: Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab2006; 91: 4237–4245.
16.
HuangABrennanKAzzizR: Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril2010; 93: 1938–1941.
17.
HullMG: Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol1987; 1: 235–245.
18.
DunaifASegalKRFutterweitW: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes1989; 38: 1165–1174.
19.
Diamanti-KandarakisE: Insulin resistance in PCOS. Endocrine2006; 30: 13–17.
20.
SchachterlMRazielAFriedlerS: Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod2003; 18: 721–727.
21.
PalombaSFalboAZulloF: Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: A comprehensive review. Endocr Rev2009; 30: 1–50.
22.
AsuncionMCalvoRMSan MillanJL: A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab2000; 85: 2434–2438.
23.
GambineriAPelusiCManicardiE: Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes2004; 53: 2353–2358.
24.
ApiMBadogluBAkcaA: Interobserver variability of modified Ferriman—Gallwey hirsutism score in a Turkish population. Arch Gynecol Obstet2009; 279: 473–479.
25.
DeUgarteCMWoodsKSBartolucciAA: Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab2006; 91: 1345–1350.
26.
KhouryMYBaracatECPardiniDP: Polycystic ovary syndrome: clinical and laboratory evaluation. Sao Paulo Med J1996; 114: 1222–1225.
27.
GambineriAPelusiCManicardiE: Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes2004; 53: 2353–2358.
28.
BalenAHConwayGSKaltsasG: Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod1995; 10: 2107–2011.
29.
AzzizR: The evaluation and management of hirsutism. Obstet Gynecol2003; 101: 995–1007.
30.
KnochenhauerESKeyTJKahsar-MillerM: Prevalence of the polycystic ovarian syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab1998; 83: 3078–3082.
31.
AydogduIOzkanHAralY: Cyproterone acetate, spironolactone and bromocriptine treatment in patients with hirsutismus. T Klin J Gynecol Obst1992; 2: 133–138 [in Turkish].
